67-Year-Old Man With ALL, Febrile Neutropenia, and a Lower Respiratory Tract Infection

Presented by Dr Joy Sarojini Michael

*Image is representative and is not of the actual patient.

Case Presentation

A 67-year-old man recently diagnosed with B-cell acute lymphoblastic lymphoma (ALL) was started on chemotherapy. On day 10 of chemotherapy, he developed a fever of 101oF (38.3oC) and a total white blood cell count of 300 cells/mm3 with neutropenia (0% neutrophils).

He developed oral candidiasis, and blood cultures were positive for Pseudomonas aeruginosa. He was started on intravenous (IV) ceftazidime for 14 days and subsequently developed tachypnoea and respiratory distress. On examination, he had bilateral crepitations. He was taken to intensive care and mechanically ventilated.

A high-resolution computed tomography (CT) scan of the thorax was carried out (see Figure).

Figure. CT of the thorax of the patient. Image courtesy of Dr Joy Sarojini Michael.

Which of the statements below accurately describes the findings on the CT of the thorax?

  1. Non-specific changes, which are not indicative of any specific disease or condition
  2. Multiple bilateral pulmonary nodules, with ground-glass opacities suggestive of active infection (with a possibility of fungal infection)
  3. Reverse halo sign, which is suggestive of mucormycosis
  4. Findings suggestive of bilateral pulmonary embolism

Discussion:

Correct answer: 2. Although it is not possible to make a definitive diagnosis based on CT imaging alone, the characteristic pulmonary nodules surrounded by ground glass opacities in a patient with this history do suggest infection. As fungal infections are common, this CT is suggestive of pulmonary fungal disease.

Answer 1 is incorrect. The changes on the CT are quite specific (nodules with ground-glass opacities), pointing towards an infection, although other tests are required to confirm this and determine the cause of infection.1

Answer 3 is incorrect. The reverse halo sign is seen when there is outer consolidation that surrounds an area of ground-glass opacity, and although it is suggestive of mucormycosis, it is not pathognomonic. All the areas seen on the CT scan have the consolidation in the centre with a ground-glass appearance surrounding it. So, this answer is incorrect.1

Answer 4 is incorrect. CT alone is usually insufficient to diagnose pulmonary embolism, and CT pulmonary angiography is usually required.2

How will you manage this case?

  1. Change the antibiotics from ceftazidime to meropenem and add liposomal amphotericin B
  2. Send sputum for bacterial and fungal culture
  3. Send a serum sample for the beta-D-glucan and Aspergillus galactomannan antigen tests
  4. Transfer the patient to a negative pressure isolation room and test for pulmonary tuberculosis

Discussion:

Correct answer: 3. This clinical picture of ALL and febrile neutropenia with the CT of the thorax showing bilateral pulmonary nodules and ground-glass opacities is highly suggestive of a fungal infection. Thus, performing rapid serological tests on serum to detect an invasive fungal infection, like Aspergillus galactomannan (GM) or Beta-D-glucan (BDG) antigen, will help establish the fungal etiology so that appropriate antifungal therapy can be started. Aspergillus GM is a specific cell-wall antigen found in Aspergillus species, and BDG is a cell-wall antigen detectable in a wide variety of pathogenic fungi except Mucorales, Cryptococcus species, and Blastomyces species.1,3

These serological tests can give a positive result (as in this case) even if the culture is negative or the fungal species is nonculturable.

Answer 2 is reasonable but not ideal. Although sputum culture is helpful for diagnosis of lower respiratory tract infections, it is difficult to obtain in a critically ill patient with respiratory distress.

Answer 1 is incorrect. There is no need to change from a narrow-spectrum antibacterial drug to a broad-spectrum drug in this patient, as there is clearly a new source of infection that needs to be identified and treated.

Answer 4 is incorrect. The findings of the thorax CT and the duration of symptoms in this patient do not clinically indicate tuberculosis (TB). However, the World Health Organization recommends that rapid molecular tests like Xpert MTB/Rif assay be performed on the sputum or respiratory sample to rule out TB in a tuberculosis-endemic county.4

Case continued: Results of Investigations:

Test Results

Question: What is the probable diagnosis?

  1. Pneumocystis jirovecii infection
  2. Invasive aspergillosis
  3. Tuberculosis

Discussion:

Correct answer: 2. BDG is a pan-fungal antigen present in many fungi such as Candida spp., Pneumocystis jirovecii, Aspergillus spp., Acremonium spp., and Fusarium spp. It is not found in Cryptococcus spp., Mucorales, and the yeast phase of Blastomyces dermatitidis. The Aspergillus GM ELISA detects Aspergillus cell-wall polysaccharide (GM) that is released during fungal growth and subsequently is detectable in serum and other body fluids. Since both the BDG and Aspergillus GM are positive in this patient, the most likely diagnosis is invasive aspergillosis.1,3

Answer 1 is incorrect. Pneumocystis jirovecii is a unicellular, intracellular fungus that cannot be cultured in vitro but can only be detected in the laboratory by microscopic methods or molecular techniques such as real-time PCR. Studies have shown that PCR has better sensitivity than microscopy in diagnosing lung infection, so the disease can be ruled out in this patient as the PCR is negative.1 While BDG can be positive with Pneumocystis jirovecii,3 the positive GM in this case lends more weight to an invasive aspergillosis diagnosis.

Answer 3 is incorrect. Xpert MTB/Rif assay is a rapid and accurate real-time PCR for the detection of pulmonary TB. In this patient, the test is negative. Also, the high-resolution CT is also not suggestive of TB.

Case Continues

The endotracheal aspirate was sent to the microbiology laboratory for bacterial, fungal, and mycobacterial cultures. The results are as follows:

  • Bacterial culture: Moderate growth of normal flora
  • Mycobacterial culture: No growth
  • Fungal culture: Direct microscopy showed septate fungal hyphae; culture grew bluish-green, pigmented, velvety fungal colonies

Question: Based on the above colony morphology, what is your likely fungal isolate?

  1. Candida albicans
  2. Rhizopus oryzae
  3. Aspergillus fumigatus

Discussion:

Correct answer: 3. Aspergillus fumigatus is a filamentous fungus that grows on Sabouraud’s dextrose agar. Colonies are typically blue-green with a suede-like or velvety appearance.5 Moreover, the finding of septate fungal hyphae seen on direct microscopy from the endotracheal aspirate is more consistent with Aspergillus fumigatus than Rhizopus oryzae or Candida albicans.6,7

Answer 2 is incorrect. Rhizopus oryzae belongs to the order Mucorales. This fungus produces sparsely septate or aseptate hyphae in tissue and grows on Sabouraud’s dextrose agar as white, woolly, or cottony colonies.8

Answer 3 is incorrect. Candida albicans is a yeast that produces pasty, cream-coloured, spherical, dome-shaped colonies in culture and is seen as budding oval yeasts and pseudo hyphae in tissue.9

Case Continued

Based on the above identification of fungus in the ET aspirate, the patient’s neutropenic status, and ease of access, amphotericin B was selected as the therapy.10,11  Voriconazole or isavuconazole would have been reasonable options as well.12

Resources

    1. Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71(6):1367-1376. doi:10.1093/cid/ciz1008.
    2. Palm V, Rengier F, Rajiah P, Heussel CP, Partovi S. Acute pulmonary embolism: imaging techniques, findings, endovascular treatment and differential diagnoses. Rofo. 2020;192(1):38-49. doi:10.1055/a-0900-4200.
    3. Theel ES, Doern CD. β-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51(11):3478-3483. doi:10.1128/JCM.01737-13.
    4. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: Policy update. 2013. Accessed October 1, 2024. Available at https://iris.who.int/bitstream/handle/10665/112472/9789241506335_eng.pdf?sequence=1 .
    5. Bora S, Sanduri A, Muthyala A. Incidence of aspergillosis in different avian species. Indian Journal of Veterinary Pathology. 2023;47. doi:10.5958/0973-970X.2023.00065.
    6. Borman AM, Johnson Em. Interpretation of fungal culture results. Curr Fungal Infect Rep. doi: 10.1007/s12281-014-0204-z
    7. Kelly BT, Pennington KM, Limper AH. Advances in the diagnosis of fungal pneumonias. Expert Rev Respir Med. 2020;14(7):703-714. doi:10.1080/17476348.2020.1753506. Epub 2020 Apr 21. PMID: 32290725; PMCID: PMC7500531.
    8. Tabarsi P, Khalili N, Pourabdollah M, Sharifynia S, Safavi Naeini A, Ghorbani J, Mohamadnia A, Abtahian Z, Askari E. Case report: COVID-19-associated rhinosinusitis mucormycosis caused by Rhizopus arrhizus: A rare but potentially fatal infection occurring after treatment with corticosteroids. Am J Trop Med Hyg. 2021;105(2):449-453. doi:10.4269/ajtmh.21-0359.
    9. Stefanetti V, Marenzoni ML, Lepri E, Coletti M, Casagrande Proietti P, Agnetti F, Crotti S, Pitzurra L, Del Sero A, Passamonti F. A case of Candida guilliermondii abortion in an Arab mare. Med Mycol Case Rep. 201;4:19-22. doi:10.1016/j.mmcr.2014.02.003.
    10. Carmo, A., Rocha, M., Pereirinha, P., Tomé, R., Costa, E. Antifungals: from pharmacokinetics to clinical practice. 2023;12:884. doi: 10.3390/antibiotics12050884
    11. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev. 2014 Feb 24;2014(2):CD004707. doi: 10.1002/14651858.CD004707.
    12. Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002.

Chair

Ruth Ashbee, PhD

Honorary Principal Clinical Scientist, Mycology Reference Center, Leeds, UK
Visiting Lecturer in the School of Molecular and Cellular Biology at the University of Leeds
Chair, British Society for Medical Mycology Therapeutic Drug Monitoring Guidelines Working Party
Fellow of the European Confederation of Medical Mycology
Leeds, United Kingdom

Faculty

Barbara Alexander, MD

Vice Chief of Transplant/Immunocompromised Host Infectious Diseases Services
Head of Clinical Mycology Laboratory
Professor of Medicine and Pathology
Duke University School of Medicine
Durham, North Carolina, USA

Beatriz L. Gómez, PhD

Professor, School of Medicine
Universidad del Rosario
Bogotá, Colombia

Rita Oladele, PhD

Clinical Microbiologist
Associate Professor and Clinical Consultant at University of Lagos and Lagos University Teaching Hospital
Fellow of the European Confederation of Medical Mycology
Fellow of the Royal College of Pathology
Chair of Pan Africa Mycology Working Group
Lagos, Nigeria

Joy Sarojini Michael, MD FRCPath

Professor & Clinical Microbiologist
Christian Medical College, Vellore, Tamil Nadu, India
Vice Chair of Tamil Nadu State TB Task Force Committee
Tamil Nadu, India

Alida Fe Talento, MD

Researcher and Consultant Microbiologist at Children’s Health Ireland
Clinical Senior Lecturer in the Department of Clinical Microbiology, Trinity College Dublin
Honorary Clinical Associate Professor in the Department of Microbiology at the Royal College of Surgeons
Dublin, Ireland  

Angela M. Tobón, MD

Lecturer-Investigator
Institution of Tropical Medicine
Universidad CES
Medellín, Colombia

Computer System Requirements

To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).

Privacy Policy

Terranova Medica, LLC, and ISHAM are committed to protecting the privacy of those who choose to participate in activities on funguseducationhub.org. The information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of personal information
Terranova Medica, LLC, and ISHAM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.

For further information, contact Tom Davis by telephone (877-276-4523), or by email (tdavis@terranovamedica.com).

Copyright © 2024 ISHAM, and Terranova Medica, LLC